Risk assessment

Risk assessment, in European drug control, is the formal scientific and policy review by which a designated EU expert body evaluates the health and social harms of a newly detected psychoactive substance and produces the evidence report on which a control decision can be based. The procedure is specific to the EU framework and does not transfer directly to other legal systems, where equivalent reviews go by different names and follow different criteria.

The body that conducted these reviews was for many years the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), based in Lisbon. In 2023 the EMCDDA was reconstituted as the European Union Drugs Agency (EUDA), which now carries the function forward.

What it means in practice

The procedure is triggered when a substance enters the EU early-warning system — a surveillance network fed by forensic laboratories, hospitals, and national focal points. The agency assembles available data on pharmacology, toxicology, prevalence, and social harm, then convenes an expert panel whose written assessment becomes the formal record.

The resulting report goes to the European Commission and the Council of the EU. If the assessment finds sufficient risk, the Council may adopt a decision placing the substance under control measures across member states — bypassing the need for each country to act independently. The process has been used most extensively for novel psychoactive substances such as synthetic cannabinoids, cathinones, and designer opioids, which emerge faster than scheduled-by-name systems can respond.

A risk assessment is not itself a scheduling act: it is the evidentiary step before one. A substance can be assessed and found to pose low risk, in which case no control decision follows.

How jurisdictions vary

The term risk assessment appears across many national drug-control systems but describes different procedures depending on the framework. In the United Kingdom, the Advisory Council on the Misuse of Drugs (ACMD) carries out analogous technical reviews before a substance can be classified under the Misuse of Drugs Act 1971; the ACMD's recommendations are advisory and can be overridden by government ministers. In the United States, the Drug Enforcement Administration conducts a scheduling review under the Controlled Substances Act, applying a different statutory test.

A substance that has received an EU control decision following a risk assessment may be entirely unscheduled in countries outside the EU's jurisdiction, or may have been independently scheduled years earlier or later under wholly different criteria.

What is contested

Risk assessments for novel psychoactive substances are sometimes conducted before robust human-safety data exists — case reports and forensic seizure records may be the primary evidence at the time of review. Researchers in the field have noted that this can result in control decisions resting on a limited empirical base, while regulators argue that the precautionary approach is appropriate given the speed at which novel substances circulate.

The phrase no currently accepted medical use appears in some national control frameworks and is sometimes reflected in EU-level reasoning. It describes a legal classification — an absence of regulatory approval — not a scientific verdict on research potential or therapeutic utility. Several substances controlled under this framing have subsequently entered formal clinical investigation.

Scope and currency

This entry is not legal advice and does not describe the law in any particular jurisdiction. Control procedures, agency mandates, and the outcomes of risk assessments change and vary substantially across countries. This entry states the position as of 21 August 2026. For the legal status of a specific substance, consult that substance's dedicated legal status section, which carries its own jurisdiction, date, and cited source.